Naslov
Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study

Autori
Vervloet, Marc G ; Boletis, Ioannis N ; de Francisco, Angel L M ; Kalra, Philip A ; Ketteler, Markus ; Messa, Piergiorgio ; Stauss-Grabo, Manuela ; Derlet, Anja ; Walpen, Sebastian ; Perrin, Amandine ; Ficociello, Linda H ; Rottembourg, Jacques ; Wanner, Christoph ; Cannata-Andía, Jorge B ; Fouque, Denis

Izvornik
Clinical Kidney Journal (2048-8513) 14 (2021), 7; 1770-1779

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
chronic kidney disease ; end-stage kidney disease ; haemodialysis ; phosphate binder ; peritoneal dialysis

Sažetak
Background: The iron-based phosphate binder (PB), sucroferric oxyhydroxide (SFOH), is indicated to control serum phosphorus levels in patients with chronic kidney disease on dialysis. Methods: This non-interventional, prospective, multicentre, cohort study conducted in seven European countries evaluated the safety and effectiveness of SFOH in dialysis patients with hyperphosphataemia in routine practice. Safety outcomes included adverse drug reactions (ADRs) and changes in iron-related parameters. SFOH effectiveness was evaluated by changes-from-baseline (BL) in serum phosphorus and percentage of patients achieving in-target phosphorus levels. Results: The safety analysis set included 1365 patients (mean observation: 420.3 +/- 239.3 days). Overall, 682 (50.0%) patients discontinued the study. Mean SFOH dose during the observation period was 1172.7 +/- 539.9 mg (2.3 pills/day). Overall, 617 (45.2%) patients received concomitant PB(s) during SFOH treatment. ADRs and serious ADRs were observed for 531 (38.9%) and 26 (1.9%) patients. Most frequent ADRs were diarrhoea (194 patients, 14.2%) and discoloured faeces (128 patients, 9.4%). Diarrhoea generally occurred early during SFOH treatment and was mostly mild and transient. Small increases from BL in serum ferritin were observed (ranging from +12 to +75 mu g/L). SFOH treatment was associated with serum phosphorus reductions (6.3 +/- 1.6 mg/dL at BL versus 5.3 +/- 1.8 mg/dL at Month 30 ; Delta BL: -1.0 mg/dL, P<0.01). Percentage of patients achieving serum phosphorus <= 4.5 mg/dL increased from 12.0% at BL to 34.8% at Month 30, while the percentage achieving serum phosphorus <= 5.5 mg/dL increased from 29.9% to 63.0%. Conclusions: SFOH has a favourable safety and tolerability profile in a real-world setting, consistent with results of the Phase 3 study. Moreover, SFOH improved serum phosphorus control with a low daily pill burden.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA